To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Global Hyperphosphatemia Therapeutics Market size was valued at USD 3.1 billion in 2021 and is poised to grow from USD 3.3 billion in 2022 to USD 4.2 billion by 2030, growing at a CAGR of 6.5% in the forecast period (2023-2030).

The Global Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the global Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi Genzyme', 'Keryx Biopharmaceuticals, Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Vifor Pharma Management Ltd.', 'Amgen Inc.', 'F. Hoffmann-La Roche Ltd.', 'AstraZeneca plc', 'Pfizer Inc.', 'Relypsa, Inc.', 'Ardelyx, Inc.', 'Velphoro (Fresenius Medical Care AG & Co. KGaA)', 'Phoslyra (Fresenius Medical Care AG & Co. KGaA)', 'Renvela/Renagel (Sanofi Genzyme)', 'Fosrenol (Shire)', 'Kayexalate (Sanofi Genzyme)', 'Ferumoxytol (AMAG Pharmaceuticals, Inc.)', 'Etelcalcetide (Amgen Inc.)', 'Parsabiv (Amgen Inc.)', 'Patiromer (Relypsa, Inc.)', 'Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)'

The increasing prevalence of chronic renal disease worldwide is one of the key factors propelling the market's growth. Due to its expanding global impact, it is predicted that by 2040, chronic kidney disease (CKD) would rank as the fifth most common cause of years lost globally. The overall number of individuals receiving dialysis has increased globally as a result of the rising prevalence of CKD. 785,883 Americans needed kidney transplants and dialysis in 2018, according to the National Kidney Foundation Inc. Of these people, dialysis was utilized to replace renal function in 554 338 cases. Nearly all dialysis-dependent renal failure patients experience hyperphosphatemia at some point in their lives. Additionally, according to the National Center for Biotechnology Information (NCBI), phosphate binders are used to treat 80–85% of dialysis patients who have hyperphosphatemia. Therefore, the market's growth during the forecast period will be greatly supported by the rising prevalence of chronic renal diseases.

A shift towards the adoption of non-phosphate binders is the key trend in the market. It is quite difficult to achieve ideal phosphate management in CKD patients receiving dialysis. The ability to manage phosphate levels in dialysis patients has not significantly improved despite the advancements in dialysis procedures throughout the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the development of novel hyperphosphatemia medicines and revising the treatment recommendations in order to improve the therapy choice for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3).

The Global Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.

Feedback From Our Clients

Global Hyperphosphatemia Therapeutics Market

Product ID: SQSG35I2014